This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): MK-0952
Description: MK-0952 is a phosphodiesterase type IV (PDE4) inhibitor. PDE-4 breaks down cyclic adenosine monophosphate (cAMP). cAMP participates in a series of reactions in the CREB (cAMP response element-binding) pathway, which impacts the transcription of genes (the production of RNA from DNA). This pathway may be involved in learning and memory, possibly through the formation and maintenance of synapses and growth of neurons. There is some evidence that PDE4 inhibitors have neuroprotective, neuroregenerative and anti-inflammatory properties. In preclinical studies, PDE4 inhibitors can counteract deficits in long-term memory caused by pharmacological agents, aging, or overexpression of mutant forms of human amyloid precursor proteins.
Additional information available to subscribers only: